Crossmark

Safety analysis of romiplostim, eltrombopag, and avatrombopag post-market approval: a pharmacovigilance study based on the FDA Adverse Event Reporting System

Crossref DOI link: https://doi.org/10.1186/s40360-025-00873-8

Published Online: 2025-02-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Xiaoling

Li, Yunsong

Zhuang, Wei
Funding

Funding for this research was provided by:

Natural Science Foundation of Fujian Province (2024J08304)

Natural Science Foundation of Xiamen Municipality (3502Z202371048)
License Information

Text and Data Mining valid from 2025-02-27

Version of Record valid from 2025-02-27
More Information

Article History

Received: 3 December 2024

Accepted: 19 February 2025

First Online: 27 February 2025

Declarations

:

: The present pharmacovigilance study was conducted using a public database of spontaneous reports. Given the use of deidentified data, ethical approval was not considered necessary.

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below